There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fortress Biotech (FBIO) and Baudax Bio (BXRX) with bullish sentiments.
Fortress Biotech (FBIO)
B.Riley FBR analyst Mayank Mamtani reiterated a Buy rating on Fortress Biotech today and set a price target of $9.00. The company’s shares closed last Monday at $2.96, close to its 52-week high of $3.11.
According to TipRanks.com, Mamtani is a 5-star analyst with an average return of 16.3% and a 45.2% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals, Arrowhead Pharmaceuticals, and Spectrum Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fortress Biotech with a $9.00 average price target.
See today’s analyst top recommended stocks >>
Baudax Bio (BXRX)
Oppenheimer analyst Leland Gershell maintained a Buy rating on Baudax Bio today and set a price target of $12.00. The company’s shares closed last Monday at $8.23.
According to TipRanks.com, Gershell is a 5-star analyst with an average return of 18.1% and a 49.5% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics, Outlook Therapeutics, and Soleno Therapeutics.
Baudax Bio has an analyst consensus of Strong Buy, with a price target consensus of $11.67, which is a 37.1% upside from current levels. In a report issued on February 14, Piper Sandler also maintained a Buy rating on the stock with a $11.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
